

Investors' Meeting for FY2024 1st Half Financial Results, Management Priorities and Business Strategies

Keiichi Iwata – President

October 30, 2024



Change and Innovation

~ with the Power of Chemistry ~



1. FY2024 Financial Results	04
2. Immediate-term, Concentrated Measures to Improve Business Performance	13
3. Fundamental Structural Reforms	20
3-1 Revival Strategy	22
3-2 Growth strategy	29

FY 2024 business performance



- H1 Core Operating Income on a **v-shaped recovery of 120 bn. yen yoy on strength in IT-related Chemicals and Pharmaceuticals.**
- H1 net income fell short of a positive income on FX and one-off factors related to Rabigh, but **improved substantially by approx. 70 bn. yen yoy.**
- Full year performance forecast is **100 bn. yen** in Core Operating Income and net income of **25 bn. yen, an increase of 5 bn. yen.**
- In FY2025, we aim for **Core Operating Income of 100 bn. yen based on actual performance.**

Immediate-term, Concentrated Measures to Improve Business Performance



- Promote the sale of unprofitable or non-core businesses. Upgrade the business portfolio.
- Revised upward 2-year **cash generation target to 700 bn. yen.**
- **Projecting a reduction of approx. 300 bn. yen vs. the end of last fiscal year** in interest-bearing liabilities.

Fundamental structural reforms



- **At Sumitomo Pharma, cost reductions and sales expansion of the three core products are progressing well.**
- **At Rabigh, the financial improvement plan was announced in August, and concrete schemes are under discussion.**
- In domestic P&P, **we reached agreement with Maruzen Petrochemical to consider operational optimization at Keiyo Ethylene.**
- Since October, we have launched our **new 4-segment business organization** and are accelerating drafting of a new mid-term plan.

Section

1

FY2024 Financial Results

FY2024 1st Half Performance Actual vs FY2023 1st Half Actual

(Billions of yen)

	FY2023 1st Half Actual	FY2024 1st Half Actual	Change	Reasons for change
Sales Revenue	1,186.9	1,241.4	54.5	
Core Operating Income	-96.7	29.5	126.1	See next slide.
FX gain/loss	33.6	-34.8	-68.5	As of the end of March 2024: 151.41 yen/\$ As of the end of September 2024: 142.73 yen/\$
Net losses related to PRC debt forgiveness	-	-23.3	-23.3	Net debt forgiveness losses and liability forgiveness gains (our share)
Others	-13.3	22.1	35.4	Reduction in business restructuring costs and impairment losses +24.7 bn. yen (FY2023 1H: -36.7 bn. yen → FY2024 1H: -12.0 bn. yen)
Net Income Attributable to Owners of the Parent	-76.3	-6.5	69.8	
Naphtha price	¥65,600/kl	¥77,800/kl		
Exchange rate	¥141.06/\$	¥152.78/\$		

PRC : Petro Rabigh

FY2024 1st Half Core Operating Income by Sector vs FY2023 1st Half

(Billions of yen)

	FY2023 1st Half Actual	FY2024 1st Half Actual	Change	Reasons for change
Essential Chemicals & Plastics	-44.4	-36.7	7.7	Rising MMA market prices Reduction of depreciation costs due to impairment of fixed assets, etc.
(PRC broken out)	(-29.3)	(-37.4)	(-8.1)	
Energy & Functional Materials	6.5	8.7	2.2	
IT-related Chemicals	17.8	37.5	19.7	Increase in shipment volumes of display and semiconductor materials
Health & Crop Sciences	-7.6	13.6	21.2	Increased market price of methionine, increased shipments of agrichemicals
Pharmaceuticals	-65.5	0.5	66.0	Cost reductions realized. Expanded sales of the three core products.
(Sumitomo Pharma broken out)	(-65.8)	(-0.0)	(65.8)	
Others	-3.5	5.8	9.3	Sold some shares in Sumitomo Bakelite
Total	-96.7	29.5	126.1	

FY2024 Performance Forecast vs Previous Forecast

(Billions of yen)

	FY2024 previous forecast	FY2024 Forecast	Change	Reasons for change	FY2023 Actual
Sales Revenue	2,670.0	2,600.0	-70.0		2,446.9
Core Operating Income	100.0	100.0	-	See next slide.	-149.0
FX gain/loss	-18.0	-21.0	-3.0	As of the end of March 2024: 151.41 yen/\$ (actual) As of the end of March 2025: 145.00 yen/\$ (forecast)	32.5
Net losses related to PRC debt forgiveness	-	-25.0	-25.0	Net debt forgiveness losses and liability forgiveness gains (our share)	-
Others	-62.0	-29.0	33.0	Reduction in business restructuring costs, etc.	-195.3
Net Income Attributable to Owners of the Parent	20.0	25.0	5.0		-311.8
Naphtha price	¥75,000/kl	¥76,000/kl		PRC : Petro Rabigh	¥69,100/kl
Exchange rate	¥145.00/\$	¥148.89/\$			¥144.59/\$

FY2024 Core Operating Income by Sector vs Previous Forecast

(Billions of yen)

	FY2024 previous forecast	FY2024 Forecast	Change	Reasons for change	FY2023 Actual
Essential Chemicals & Plastics	-35.0	-59.0	-24.0	Downturn in PRC performance, etc.	-90.7
Energy & Functional Materials	11.0	15.0	4.0		7.8
IT-related Chemicals	47.0	57.0	10.0	Increase in shipment volumes of display and semiconductor materials	44.0
Health & Crop Sciences	62.0	62.0	-		30.9
Pharmaceuticals	3.0	3.0	-		-133.0
(Sumitomo Pharma broken out)	(1.0)	(1.0)	(-)		(-133.0)
Others	12.0	22.0	10.0	Increase in capital gains on business dispositions	-8.0
Total	100.0	100.0	-		-149.0

PRC : Petro Rabigh


FY2024 Core Operating Income Forecast by Sector

(Billions of yen)

	FY2024 1st Half Actual	FY2024 2nd Half Forecast	FY2024 Forecast	Notes
Essential Chemicals & Plastics	-36.7	-22.4	-59.0	1Q PRC equipment failures, H2 Singapore MMA rationalization benefits
(PRC broken out)	(-37.4)	Non-disclosure	Non-disclosure	
Energy & Functional Materials	8.7	6.3	15.0	
IT-related Chemicals	37.5	19.5	57.0	Shipments solid. 4Q demand is seasonally low.
Health & Crop Sciences	13.6	48.4	62.0	4Q demand is seasonally high in NA.
Pharmaceuticals	0.5	2.5	3.0	Expanding sales of three core products, etc.
Others	5.8	16.2	22.0	Capital gains on business dispositions
Total	29.5	70.5	100.0	


PRC : Petro Rabigh

(Reference) Organizational Reorganization Overview (as of October 1, 2024) and Core Operating Income Forecast




(Billions of yen)

In FY2025, we aim to achieve 100 bn. yen in Core Operating Income organically




Shareholder returns

Maintain dividends at **annual DPS of 9 yen.**



Aim for 24 yen/share or more per year



29.9	26.9	30.5	89.9	53.3	24.2	421.2	—	58.9	Dividend payout ratio (%)
1.24	1.09	0.84	0.57	0.92	0.75	0.62	0.57		PBR


Section

2

Immediate-term, Concentrated Measures to Improve Business Performance

Progress on Immediate-term, Concentrated Measures to Improve Business Performance (Summary)

Raised cash generation target to 700 bn. yen from 600 bn. yen.

Previous targets		Current targets	
Cash generation FY 2023 - 2024	Initial target Approx. 500 bn. yen	▶ Approx. 600+ bn. yen	▶ Raised to 700 bn. yen
 Rebuild businesses	Cash generation: 150 bn. yen	▶	Cash generation: Raised to 185 bn. yen
 Reduce inventories	Reduction of approx. 150 bn. yen vs. the end of FY 2023 H1	▶	Continue to target 150+ bn. yen reduction by end of FY 2024
 More selective investments (cash basis)	150+ bn. yen reduction vs. plan (3-year cumulative)	▶	Target 200+ bn. yen in reductions through further investment curtails
 Sell assets and leverage surplus funds	Sell shareholdings: 60 bn. yen Surplus funds: 70 bn. yen Sale of other assets: 30 bn. yen	▶	Continue to target approx. 60 bn. yen ▶ Line of sight into achieving 70 bn. yen ▶ Raise to 38 bn. yen with sale of wellness facilities
Currently achieved approx. 500 bn. yen			

Progress in rebuilding businesses

Short-term cash generation and v-shaped recovery along with upgrading of business portfolio from commodities to high value-added products

Long-term vision

Innovative Solution Provider




Concentrate management resources in high value-added businesses



Rebuild businesses from a best owner perspective

- | | |
|--|--|
| Sold US post-harvest business | Sold shares in overseas aluminum smelting business |
| Sold agricultural polyolefin business | Exited cyclohexanone business |
| Optimized operations at Keiyo Ethylene | Exited resin coloring agent business |
| Exited China LCD chemicals business | Sold all Roivant shares |
| Cut Singapore MMA production capacity | Sold some shares in Sumitomo Bakelite |

- | | |
|--|---|
| <p>New herbicide Rapidicil®</p> <p>Bought maker of natural agricultural materials</p> | <p>New CDMO plant in Oita for small molecule drugs</p> |
| <p>New semiconductor process chemicals plant in US</p> <p>Added capacity in semiconductor chemicals and resists in South Korea</p> | <p>Strengthened licensing business through partner alliances</p> <p>Accelerated development of GI Fund businesses</p> |
| <p>New R&D Center in South Korea</p> | <p>Innovation Center MEGURU</p> |
| <p>Next-generation transparent LED displays</p> | <p>Sustainable materials: Noblen® and Meguri®</p> |
| | <p>New digital platform Biondo®</p> |




Progress in rebuilding businesses

Accelerate sale of noncore businesses from the perspective of best owner
 Already achieved about 95 billion yen on a cash basis.

Illustration of the status of about 30 projects to rebuild businesses

(Billions of yen)



More under study

Added projects, increasing from the previous 150 bn. yen to 185 bn. yen

Achieved

Already achieved projects worth about 95 bn. yen

< Complete AND publicly announced >

- Strengthen competitiveness in methionine and reorganize lines
- Exited cyclohexanone business
- Sold agricultural polyolefin business
- Sold resin coloring agent business
- Sold post-harvest business
- Sold all Roivant shares
(Not included in this graph.)
- Sold China LCD chemicals business

NEW

- Sold overseas aluminum smelting business
- Sold partial stake in Sumitomo Bakelite

Progress on inventory reductions and investment down-selection

Further strengthen inventory reduction and investment down-selection



Reduce inventories

By the end of March 2025
Reduction of **150+** bn. yen

Inventory balance **800** bn. yen → below **650** bn. yen





More selective investments

FY2022-2024
(3-year cumulative)

Capital investment and financing plan
Reduction of **200+** bn. yen
700 bn. yen → below **500** bn. yen

- The balance as of the end of September 2024 is 712.4 billion yen.
- Target further reductions by leveraging DX or exiting or selling businesses

- Selective investments in growth areas such as biorationals and high-performance materials
- **Further streamline by more than 50 billion yen from the previous target of 550 billion yen.**



Progress on asset dispositions and use of surplus funds

Accelerating the sale of cross-shareholdings with the aim of reducing holdings to zero.



Sale of cross shareholdings

Target : **60 bn. yen**

(by the end of FY2024)

- Have sold shares of operating companies and financial institutions (**Approx. 50 bn. Yen** as of September 2024)
- **Approx 60 bn. yen is expected**, including sales during FY2024



Surplus funds

Target : **70 bn. yen**

(by the end of FY2024)

- Leverage surplus funds at overseas group companies via group finance
- **Approx. 70 bn. yen** has already been generated by the end of FY2023.



Sale of other assets


Target : **38 bn. yen**

(by the end of FY2024)

- Have sold shares of Inabata & Co., Ltd. (**Approx. 24 bn. yen** for FY2023)
- Sale of welfare facilities, etc. (**Approx. 14 bn. yen** for FY2024)

Interest-bearing liabilities Analysis (End of FY2023→End of FY2024) SUMITOMO CHEMICAL

Financial improvement through short-term measures from the end of FY2023. Reduced interest-bearing debt by about 300 bn. yen.




Section

3

Fundamental Structural Reforms

Overview of fundamental structural reforms

Stop the bleeding and rebuild with revival strategy, then aim for sustainable growth based on new growth strategies



Section

3-1


Fundamental Structural Reforms (Revival Strategy)

Sumitomo Pharma: Progress toward positive Core Operating Income (3 key products)

Steady progress expanding sales of 3 key products driven by ORGOVYX

FY2024 sales revenue of 3 key products

(Billions of yen)



As of the end of H1

ORGOVYX better than expected

Product name	Indications	Initiatives in FY 2024
ORGOVYX	Progressive prostate cancer	<ul style="list-style-type: none"> ● Patient co-pay reduced under the IRA ● Establish position as first line drug leveraging revision to standard treatment guidelines for oncology
GEMTESA	Overactive bladder	<ul style="list-style-type: none"> ● Drive penetration of differentiation of GEMTESA leveraging its high safety ● Appropriate promotions preparing for expanded indication for overactive bladder due to enlarged prostate
MYFEMBREE	Uterine fibroids Endometriosis	<ul style="list-style-type: none"> ● Strengthen media advertising to raise awareness

Sumitomo Pharma: Progress toward positive Core Operating Income (Reductions to SG&A and R&D)

Far-reaching cost reductions have begun to take effect, contributing to improved business performance

SG&A and R&D expenses

Targets

108 bn. yen reduction yoy

Rationalizations

NA restructuring → 2 rounds in FY 23
2,200 → 1,100 employees


Shrink clinical trial costs

Impair intangible assets and reduce D&A

Reduce expenses

Japan restructuring → In Japan: Approx. 2,800 → 2,000 employees
Benefits emerge after December 2024

Progress reducing SG&A and R&D expenses



Solid progress toward full-year 108 bn. yen target

1. Financial improvement plan

Debt forgiveness

- Aramco and Sumitomo Chemical each forgive \$750m in loans
 - ▶ Substantially reduce cumulative losses and borrowings

Provide funds

- Change capital structure through share sales
 - ▶ Our share 37.5% ▶ **15.0%**
- Contribute to PRC \$702m in proceeds from share sales
- Aramco also contributes the same amount to PRC
 - ▶ Reduce interest burden by paying down debt

Progress

- Forgave \$1.0bn in debt in end of August
- Remaining \$0.5bn to be forgiven in January 2025
- **We will treat the entire amount in the first half in our consolidated financial statements**

- **Discussions continue regarding the structuring of the funding contribution**
- Began negotiations with regulatory authorities


2. Plan to strengthen earnings power

- Currently implementing the following immediate-term measures
 - Increase olefin production through de-bottlenecking of ethane cracker and HOFCC
 - Execute business performance improvement measures (Transformation Program)
- Mid- to long-term measures to be announced by PRC

Progress

- Aramco leading the execution of earnings strengthening plans
- **In discussions with Aramco on the improvement measures, including timing of disclosure**

To survive, business reorganization measures need to be more concrete



Rebuilding P&P business in Japan and Singapore (2): Keiyo Ethylene operations optimization

Sumitomo Chemical and Maruzen Petrochemical have **entered studies to optimize operations at Keiyo Ethylene**, triggered by **our request to reduce supply volumes from Keiyo Ethylene**


Background

- ✓ Emerging markets add production capacity and product flows into Japan
- ✓ Utilization of naphtha crackers in Japan decline




Forced to export low-profit ethylene and commodity resins to maintain minimum utilization rates

Keiyo area naphtha crackers*



- ✓ We asked Maruzen Petrochemical to **reduce our supply volumes from Keiyo Ethylene**. Together, we have entered studies to **optimize operations at Keiyo Ethylene**. (Per press release from Sumitomo Chemical)
- ✓ Maruzen Petrochemical is studying capacity reductions including shutting down a naphtha cracker (per press release from Maruzen Petrochemical)

Approximation of operational optimization reflecting our reduced supply volumes



* Each company's actual utilization in 2022 including production capacity including external sales and without regularly scheduled maintenance. Sourced from The Heavy & Chemical Industries News Agency's 2024 version of Japan Petrochemical Industry Association.

Rebuilding P&P business in Japan and Singapore (3): Singapore MMA production capacity reduction

Improve profitability and concentrate resources on high-margin products by substantially reducing MMA production capacity

Our MMA production capacity

(1,000 tons/year)

	MMA monomer	PMMA
Singapore	80% reduction (223) ▶ 53	70% reduction (150) ▶ 50
Japan	90	-
After reduction Total	143	50


Substantially reduce Singapore MMA production capacity



Also thoroughly rationalize organization
Integrate sales and research functions between Japan and Singapore

Realize benefits of cost reductions this second half

MMA market prices and margin



Future direction for MMA business

- Specialize in high-margin products mainly for automotive applications
- Advance recycling technological development that contributes to a reduced environmental impact and focus on solutions business



2022 : Launch validation equipment for chemical recycling in Ehime
May 2024: Strengthen licensing business through alliance with Lummus

Section

3-2

Fundamental Structural Reforms (Growth strategy)

Long-term vision :

A company that solves social issues with innovative technology

Innovative Solution Provider



Food

Achieve regenerative



ICT

Innovate IT



Healthcare

Spread leading-edge medicine



Environment


Reduce environmental impact

Business sectors

Agro & Life Solutions



ICT & Mobility Solutions



Advanced Medical Solutions



Essential & Green Materials



Important value-generation assets

G X
Green

D X
Digital


B X
Bio

Our unique 6 core technologies

Long-term targets

Set ROI targets for each Sector.

Concentrate management resources on two growth drivers and aim to achieve a core operating income of 100 billion yen in each sector in FY2030.



A G R O & L I F E S O L U T I O N S

Vision

Leverage organic chemistry technologies to contribute to the realization of a regenerative society through hybrid solutions combining chemicals with natural matter such as biorationals and botanicals

Strengths

World-class capabilities in agrochemical discovery, No. 1 market share in biorational and botanical products

New product development capabilities


Global footprint

Business strategy

- Pursue contributions to **regenerative agriculture** leveraging agrochemicals, biorationals and botanicals
- Leverage to the hilt sales footprint in growth markets such as **Brazil and India**
- Expand natural pyrethrin and deploy new botanicals
- Accelerate deployment of biorationals into **field of animal nutrition**

Strengthen presence in **European** market where strong growth in biorationals is projected

European market size



Our actions

Strengthen portfolio

Strengthen footprint

Launch new products

INDIFLIN

Biorational fruit thinner
(Accede)

Further strengthen biorationals business

Early launch of FBSciences products

Strengthen footprint and portfolio through M&A

Characteristics and trends

Longer registration evaluation periods due to strict regulations

Main crops are wheats and fruits

Products with high environmental impact drop out from the market

Greater opportunities for biorationals

I C T & M O B I L I T Y S O L U T I O N S

Vision

Integrate businesses related to ICT and mobility and fuse core technologies and our wealth of know-how to provide solutions to accelerate customer innovation.

Strengths

- Support next-generation needs with a broad range of material design and organic synthesis technology
- Fuse high-performance materials with process technology to deliver customer value
- Chemical design capabilities and know-how in high-purity chemicals
- Solutions proposal capabilities with speed and advanced technology

Business strategy

Expand business

- Aim for top share in next-generation EUV with **proprietary organic molecular resist**
- Actively introduce semiconductor back-end process materials, where technology is transitioning

Expand business geography

- Full foray into US mainly in semiconductor materials

Maximize earnings in existing businesses

- Display materials ▶ **Major portfolio shift** Shift to **high-performance materials** for OLED and automotive applications
- Silicon semiconductor materials ▶ **Strengthen supply infrastructure** in advance of demand growth
- Mobility-related materials ▶ Focus on growth areas and maximize business value

Growth topics: Semiconductor materials business expansion

Expand semiconductor materials business by strengthening our global supply infrastructure and developing back-end process materials

Semiconductor photoresist for cutting-edge processes


South Korea: Began mass production at ArF immersion photoresist plant

Established 2-plant supply regime in Japan and South Korea

■ Positioning of each plant


- Japan: Mother plant, acquisition and global deployment of manufacturing technology know-how
- S. Korea: Base of supply for S. Korean customer(s) and backup plant for BCP

■ Sumitomo Chemical increases to production capacity of semiconductor photoresist for cutting-edge processes



Semiconductor chemicals

■ Our increases to production capacity of semiconductor chemicals



■ Our business footprint for semiconductor chemicals



Accelerate development of materials for semiconductor back-end processes

■ Leverage new segment organization to fuse key materials and know-how
Accelerate development with ties to new development center in Pangyo, South Korea

Wiring materials

Packaging materials

Performance chemicals

Aim to grow **100+ bn. yen** in semiconductor materials revenues **2.5X** by 2030

A D V A N C E D M E D I C A L S O L U T I O N S

Vision

Leverage “the power of chemistry and biology” to support the health and potential of people worldwide through solutions that draw from advanced manufacturing, management and analysis technologies

Strengths

Comprehensive capabilities developed in the Life Science business

- Development, production technology, quality management, analysis

Technological superiority

- Synthesis capabilities in small- and medium-sized molecule drugs
- Synthesis technology in high-purity long-chain nucleic acids
- Cutting-edge stem cell technology

Business strategy

Regenerative medicine & cell therapies

- Accelerate deployment into US market leveraging iPS cell commercialization technology

CDMO
(small molecule, nucleic acid, regenerative medicine & cell therapies)

- Weaponize strong synthesis capabilities to achieve solid growth in CDMO business targeting small- to mid-size molecules, where development is becoming more sophisticated
- Maximize synergies with clinical therapies development in regenerative medicine & cell therapies

Expand production capacity to respond with flexibility to abundant demand

Small molecule drugs CDMO

Market conditions

Horizontal specialization of pharmaceutical companies

Multi-sourcing at customers

Increased need for stable supply and quality

Abundant demand for small molecule drugs CDMO

Production regime

Strengthen production infrastructure at Oita Works

Take over some equipment from Sumitomo Pharma and begin our own production

Small molecule drug plant completes this month



Oita: New plant for small molecule drugs

Establish structure of 3 plants in Japan, including Okayama and Gifu

Add supply capacity and enhance business continuity plan (BCP)

Oligonucleotide therapeutics CDMO

New Oita plant in operation

August 2023

Industry-leading purity is our technological strength

High-purity production of even long-chain nucleic acids with 100+ base groups

Regenerative medicine & cell therapies CDMO

Plan to complete Line 2 at S-RAMCO in July 2025



S-RAMCO Line 2 (under construction)

Sumitomo Chemical CDMO business scale*

FY23
Approx.
30 bn. yen

FY27
Approx.
50 bn. yen

*Total of small molecule, nucleic acid, regenerative medicine & cell therapies

E S S E N T I A L & G R E E N M A T E R I A L S

Vision

Establish position as a Solution Provider that maintains stable supply of materials essential to society and contributes to a reduced environmental impact

Strengths

Elemental technologies supporting development of technologies that reduce environmental impact

Track record of 71 licensing contracts in 16 countries

Capabilities running large-scale projects

Business strategy

Stabilize earnings by expanding licensing and catalyst businesses

Expand businesses that reduce environmental impact

(Examples of candidate technologies)

- Ethanol to propylene
- CO₂ to methanol (ICR)
- Olefins from direct cracking of waste plastic
- PMMA chemical recycling, etc.



Growth strategy topics: Development of technologies that reduce environmental impact

UPDATE on Green Innovation Fund* businesses *A 2 trillion yen fund established to provide up to 10 years of aid for ambitious corporate R&D and validation initiatives aimed at achieving carbon neutrality

Technology		Progress	Stage	Commercialization target
Chemical recycling	Production of olefins by direct cracking of waste plastics	<ul style="list-style-type: none"> Leverage waste plastics as an input to achieve targeted olefins yield of 60% Confirm sufficient catalyst life 	<p>Bench scale In testing</p>	Early 2030s
	Highly efficient alcohol production from CO ₂	<ul style="list-style-type: none"> In test production of methanol from CO₂ Achieve 80% methanol yield, far higher than theoretical values 	<p>Pilot scale In testing</p>	
	Olefin production from alcohols	<ul style="list-style-type: none"> Use ethanol as an input to achieve targeted olefins yield of 80% Pilot equipment to be completed in first half of 2025 (Chiba Works) 	<p>Bench scale In testing</p> <p>Pilot facilities Under construction</p>	

Growth strategy topics: Development of technologies that reduce environmental impact

Innovation Center MEGURU is finally complete

Transform Chiba into research laboratory for technologies that reduce environmental impact

Main R&D themes

- Technologies that reduce environmental impact
- Development of very difficult polymer materials such as next-generation mobility and 5G materials

Strengths of our laboratories


- Elemental technologies in polymer design, catalysts, process, and processing
- Know-how and validation equipment for scaling up
- Consolidate people and equipment for development of high-performance chemicals from multiple, dispersed locations into one and achieve synergies



Innovation Center
MEGURU

Toward sustainable growth

First and foremost, a V-shaped recovery is a must. Then, we strengthen our financial standing and return to a growth trajectory.



Cautionary Statement

Statements made in this document with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it and involve risks and uncertainties.

The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.